ClinicaliQ Trial Snapshot
- A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn’s Disease — Active Not Recruiting • Phase III • Gastroenterology • NCT05347095.
- Guselkumab (IL-23 inhibitor) tested for treating perianal fistulas in Crohn's disease patients, measuring effectiveness and safety.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study to evaluate the clinical efficacy of guselkumab in fistulizing, perianal Crohn's disease and to assess the overall safety of guselkumab. Conditions: Fistulizing Crohns Disease, Perianal Crohns Disease Interventions: Guselkumab, Placebo Lead Sponsor: Janssen-Cilag Ltd. Planned Enrollment: 288 participants